NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundMitochondrial dysfunction is a central pathogenic mechanism in Parkinson's disease (PD), particularly in genetic forms associated with respiratory chain impairment. Disease-modifying therapies capable of restoring neuronal bioenergetics while achieving non-invasive brain delivery remain lacking. This study investigated the therapeutic potential of an arginine-enriched penetratin-derived peptide (PenArg) in a genetic PD model carrying the UQCRC1 (p.Tyr314Ser) mutation.MethodsThe effects of PenArg labeled with 5-FAM- or biotin were evaluated in UQCRC1 knock-in SH-SY5Y cells and mice. Mitochondrial function, neuronal survival, and apoptosis were assessed using biochemical and imaging analyses. Brain distribution was evaluated 2 h after intranasal administration, and therapeutic efficacy was examined following chronic intranasal treatment (three times weekly for six months).ResultsPenArg restored mitochondrial membrane potential, improved neuronal viability, and reduced oxidative stress-induced apoptosis in cellular models. Imaging studies demonstrated partial mitochondrial localization in vitro and in vivo. Intranasal administration significantly improved locomotor performance, preserved dopaminergic neurons in the substantia nigra (SN) and striatum, and maintained hippocampal neuronal structure. Brain distribution analysis confirmed widespread brain penetration after intranasal administration. PenArg restored ATP synthase subunit beta expression and complex III activity while reducing cytochrome c release and caspase-3 activation in SN neurons. Treatment additionally attenuated skeletal muscle atrophy, enhanced antioxidant responses, and reduced circulating pro-inflammatory cytokines.ConclusionPenArg confers neuroprotection through functional modulation of mitochondrial homeostasis and produces multisystem therapeutic benefits. Intranasal administration represents a non-invasive strategy with disease-modifying potential for mitochondrial-related neurodegenerative disorders.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.